New drug shows promise in High-Risk eye cancer trial
NCT ID NCT05187884
First seen May 03, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This Phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma, a rare eye cancer. Participants took the drug for up to 4 weeks before eye removal surgery, and some continued for 6 months after. The main goal was to see if the treatment is safe and tolerable, and to measure its effects on tumor size and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
Kinghorn Cancer Centre, St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Darovasertib (oral tablet)
What this could lead to
If successful, this could point toward a new treatment option for uveal melanoma that may help control the disease before and after surgery.
What could go wrong
This is a very small, early-phase trial with only 15 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.